176 related articles for article (PubMed ID: 33805713)
1. Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.
Ung C; Tsoli M; Liu J; Cassano D; Pocoví-Martínez S; Upton DH; Ehteda A; Mansfeld FM; Failes TW; Farfalla A; Katsinas C; Kavallaris M; Arndt GM; Vittorio O; Cirillo G; Voliani V; Ziegler DS
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33805713
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
3. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery.
Alli S; Figueiredo CA; Golbourn B; Sabha N; Wu MY; Bondoc A; Luck A; Coluccia D; Maslink C; Smith C; Wurdak H; Hynynen K; O'Reilly M; Rutka JT
J Control Release; 2018 Jul; 281():29-41. PubMed ID: 29753957
[TBL] [Abstract][Full Text] [Related]
4. Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma.
Sasaki T; Watanabe J; He X; Katagi H; Suri A; Ishi Y; Abe K; Natsumeda M; Frey WH; Zhang P; Hashizume R
J Neurosurg; 2023 Jun; 138(6):1570-1579. PubMed ID: 36599085
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.
Tsoli M; Liu J; Franshaw L; Shen H; Cheng C; Jung M; Joshi S; Ehteda A; Khan A; Montero-Carcabosso A; Dilda PJ; Hogg P; Ziegler DS
Oncotarget; 2018 Jan; 9(7):7541-7556. PubMed ID: 29484131
[TBL] [Abstract][Full Text] [Related]
6. Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.
Amani V; Prince EW; Alimova I; Balakrishnan I; Birks D; Donson AM; Harris P; Levy JM; Handler M; Foreman NK; Venkataraman S; Vibhakar R
BMC Cancer; 2016 Aug; 16():647. PubMed ID: 27538997
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
8. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
[TBL] [Abstract][Full Text] [Related]
9. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
10. Intersection of Brain Development and Paediatric Diffuse Midline Gliomas: Potential Role of Microenvironment in Tumour Growth.
Loveson KF; Fillmore HL
Brain Sci; 2018 Nov; 8(11):. PubMed ID: 30453529
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
Halvorson KG; Barton KL; Schroeder K; Misuraca KL; Hoeman C; Chung A; Crabtree DM; Cordero FJ; Singh R; Spasojevic I; Berlow N; Pal R; Becher OJ
PLoS One; 2015; 10(3):e0118926. PubMed ID: 25748921
[TBL] [Abstract][Full Text] [Related]
12. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
13. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
[TBL] [Abstract][Full Text] [Related]
14. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.
Welby JP; Kaptzan T; Wohl A; Peterson TE; Raghunathan A; Brown DA; Gupta SK; Zhang L; Daniels DJ
Front Oncol; 2019; 9():92. PubMed ID: 30873381
[TBL] [Abstract][Full Text] [Related]
15. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
16. Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas.
Faisal SM; Mendez FM; Nunez F; Castro MG; Lowenstein PR
Oncotarget; 2020 Dec; 11(50):4607-4612. PubMed ID: 33400737
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
18. Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.
Patel SK; Hartley RM; Wei X; Furnish R; Escobar-Riquelme F; Bear H; Choi K; Fuller C; Phoenix TN
Neuro Oncol; 2020 Mar; 22(3):381-392. PubMed ID: 31638150
[TBL] [Abstract][Full Text] [Related]
19.
Kluiver TA; Alieva M; van Vuurden DG; Wehrens EJ; Rios AC
Front Oncol; 2020; 10():92. PubMed ID: 32117746
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
